Belvedere Trading’s Recursion Pharmaceuticals RXRX Stock Holding History

Belvedere Trading’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,500	Closed	-$42.1K	–	981
2023 Q3	$42.1K	Buy	+5,500	New	+$54.9K	﹤0.01%	439
2021 Q4	–	Sell	-200	Closed	-$4K	–	603
2021 Q3	$4K	Buy	+200	New	+$5.67K	﹤0.01%	467

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Belvedere Trading's RXRX Position: Q4 2023 in Review

Belvedere Trading sold out of Recursion Pharmaceuticals (RXRX) in Q4 2023, closing a stake of 6,340 shares — an estimated $48.5K sold.

Belvedere Trading first reported a position in RXRX in Q3 2023 and held it in 1 quarter. The position peaked at $48.5K in Q3 2023. 199 funds tracked by Wall St. Rank hold RXRX as of Q4 2023.

Belvedere Trading reported no remaining Recursion Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Belvedere Trading sold 6,340 Recursion Pharmaceuticals shares in Q4 2023, an estimated $48.5K.
Belvedere Trading first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 1 quarter.
Belvedere Trading's Recursion Pharmaceuticals position peaked at $48.5K in Q3 2023.
199 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.